Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Published Results
Trial Contact Information
Registry Information

Alternate Title

Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs Phase III Treatment Closed 18 and over NCI ECOG-E1899 SWOG-E1899, CALGB-E1899, E1899, NCT00027859

Special Category: CTSU trial

Objectives

1. Compare time to objective progression in patients with prostate cancer and a rising prostate-specific antigen (PSA) after androgen suppression when treated with second-line hormonal therapy (ketoconazole and hydrocortisone) vs combination chemotherapy (docetaxel and estramustine).
2. Compare time to PSA progression and correlate this with time to objective progression in patients treated with these regimens.
3. Compare the quality of life in patients treated with these regimens.
4. Compare overall survival of patients treated with these regimens.
5. Compare the natural history of progression in patients treated with these regimens.
6. Identify prognostic indicators of clinical outcome by immunohistochemical evaluation of apoptopic biomarkers in patients treated with these regimens.

Entry Criteria

Disease Characteristics:

• Histologically confirmed adenocarcinoma of the prostate that was continuously treated with androgen suppression



• Rising prostate-specific antigen (PSA), defined as PSA > 5 ng/mL, rising on 2 consecutive measurements at least 4 weeks apart



• Gleason score 7 or higher and/or seminal vesicle involvement at diagnosis



• Patients previously treated with antiandrogen or glucocorticoid therapy must meet the following criteria:
  • Must show a continued rise in PSA after stopping antiandrogen (flutamide, bicalutamide, or nilutamide) or glucocorticoid (dexamethasone or prednisone)
    • At least 4 weeks continued rise in PSA after flutamide or nilutamide (6 weeks for bicalutamide)



• Testosterone less than 50 ng/dL
  • Patients who have not undergone surgical castration must continue primary androgen suppression to maintain castrate levels of testosterone



• No progressive or measurable local or metastatic disease (including bone metastases)

Prior/Concurrent Therapy:

Biologic therapy:

• Not specified

Chemotherapy:

• At least 5 years since prior systemic chemotherapy

Endocrine therapy:

• See Disease Characteristics
• At least 4 weeks since prior hydrocortisone
• No prior ketoconazole

Radiotherapy:

• At least 28 days since prior radiotherapy to primary site
• No prior palliative radiotherapy
• No concurrent radiotherapy

Surgery:

• See Disease Characteristics

Other:

• Recovered form prior therapy
• At least 7 days since prior parenteral antibiotics for active infection
• No concurrent digitalis
• No concurrent H₂ blockers or proton pump inhibitors (arm I only)
• Concurrent bisphosphonates allowed provided they were initiated prior to study therapy

Patient Characteristics:

Age:

• 18 and over

Performance status:

• ECOG 0-1

Life expectancy:

• Not specified

Hematopoietic:

• Granulocyte count at least 2,000/mm³
• Platelet count at least 100,000/mm³

Hepatic:

• SGOT no greater than 2 times upper limit of normal
• Bilirubin no greater than 1.5 mg/dL

Renal:

• Creatinine no greater than 1.7 mg/dL

Cardiovascular:

• No American Heart Association class III or IV heart disease
• No uncontrolled congestive heart failure
• No life-threatening cardiac arrhythmias

Other:

• Fertile patients must use effective contraception
• No other prior malignancy unless curatively treated and disease-free for appropriate time period for specific cancer
• No preexisting peripheral neuropathy greater than grade 1
• No known hypersensitivity to polysorbate 80

Expected Enrollment

A total of 590 patients (295 per treatment arm) will be accrued for this study within 4 years.

Outline

This is a randomized, multicenter study. Patients are stratified according to prior treatment with bisphosphonates (yes vs no). Patients are randomized to 1 of 2 treatment arms.

• Arm I: Patients receive oral ketoconazole three times daily and oral hydrocortisone twice daily. Treatment continues in the absence of disease progression or unacceptable toxicity.



• Arm II: Patients receive oral estramustine three times daily on days 1-5 and docetaxel IV over 1 hour on day 2. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline, on day 1 of week 9, at 6 months and 1 year, and then annually for up to 10 years or until beginning of first non-protocol therapy.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually for 5 years.

Walczak JR, Carducci MA; Eastern Cooperative Oncology Group E1899.: Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Group (E1899), Intergroup/Clinical Trials Support Unit study. Urology 62 (Suppl 1): 141-6, 2003.[PUBMED Abstract]

Trial Contact Information

Trial Lead Organizations

Eastern Cooperative Oncology Group

Michael Carducci, MD, Protocol chair		Ph: 410-614-3977 Email: carducci@welchlink.welch.jhu.edu

Southwest Oncology Group

Nirmala Bhoopalam, MD, Protocol chair		Ph: 708-202-2782 Email: nirmala.bhoopalam@med.va.gov
Gregory Swanson, MD, Protocol co-chair(Contact information may not be current)		Ph: 509-473-1600 Email: greg.swanson@usoncology.com

Cancer and Leukemia Group B

William Dahut, MD, Protocol chair		Ph: 301-435-8183 Email: dahutw@mail.nih.gov

Registry Information
Official Title		A Phase III Randomized Trial for Evaluating Second Line Hormonal Therapy (Ketoconazole/Hydrocortisone) Versus Paclitaxel/Estramustine Combination Chemotherapy on Progression Free Survival in Asymptomatic Patients with a Rising PSA After Hormonal Therapy for Prostate Cancer
Trial Start Date		2003-05-01
Registered in ClinicalTrials.gov		NCT00027859
Date Submitted to PDQ		2001-10-17
Information Last Verified		2004-08-16
NCI Grant/Contract Number		U10-CA21115

Back to Top